MicroRNA-214 exerts a Cardio-protective effect by inhibition of fibrosis

Hua Dong1, Shimin Dong2, Lisi Zhang1

  • 1Department of Histology and Embryology, Hebei Medical University, Shijiazhuang, 050017, China.

Insights

MicroRNA-214 (miR-214) protects the heart by inhibiting cardiac fibrosis. It reduces collagen production and regulates key fibrotic factors like TGF-β1, offering a potential therapeutic target for heart conditions.

Area of Science:

  • Cardiovascular Biology
  • Molecular Cardiology
  • Fibrosis Research

Background:

  • MicroRNAs (miRNAs) are crucial regulators of myocardial fibrosis.
  • MicroRNA-214 (miR-214) has a potential but uncharacterized role in cardiac fibrosis.

Purpose of the Study:

  • To investigate the role of miR-214 in regulating cardiac fibrosis both in vitro and in vivo.
  • To elucidate the molecular mechanisms underlying miR-214's effect on cardiac fibrosis.

Main Methods:

  • In vitro: Angiotensin II (Ang II)-induced cardiac fibroblasts (CFBs) transfected with miR-214 mimics or inhibitors.
  • In vivo: Acute myocardial infarction (AMI) model in rats with Ad-pre-miR-214 or Ad-anti-miR-214 delivery.
  • Gene and protein expression analysis using qRT-PCR and Western blotting.

Main Results:

  • In vitro, miR-214 transfection reversed Ang II-induced increases in collagen type I (COL I), collagen type III (COL III), transforming growth factor-β1 (TGF-β1), and tissue inhibitors of metalloproteinase-1 (TIMP-1), while increasing matrix metalloproteinase-1 (MMP-1).
  • In vivo, miR-214 overexpression attenuated increases in COL I, COL III, and TGF-β1 post-AMI and increased MMP-1 expression.
  • miR-214 inhibition showed opposite effects, exacerbating fibrosis markers.

Conclusions:

  • miR-214 exhibits significant cardio-protective effects by inhibiting myocardial fibrosis.
  • The mechanism involves suppression of TGF-β1 and regulation of MMP-1/TIMP-1 balance.
  • miR-214 represents a potential therapeutic target for treating cardiac fibrosis.

Related Concept Videos